Sign in
Already have access? Choose your edition
Sign-in is edition-specific. New here? Start with the free brief instead of jumping straight into a trial.
Each edition has its own app, pricing, and coverage page. Use sign-in if you already have access; otherwise pick an edition and get the free daily + weekly brief first.
AI
Daily briefings on AI labs, policy, tooling, and community shifts.
Best for
- Model releases + evals
- Policy and safety narratives
- Tooling and platform shifts
Flagship sampleUnlocked today
Coverage centers on: Military AI Policy Needs Democratic Oversight.
Crypto
Daily briefings on markets, protocols, narratives, and risk events.
Best for
- Market structure + regulation
- Security and exploit narratives
- Protocol + dev ecosystem
Flagship sampleUnlocked today
Coverage centers on: Bitcoin Braces for $60,000 Retest: What Technical Indicators Say About March Outlook.
CYBERSECURITY
Daily briefings on vulnerabilities, incidents, and threat intel.
Best for
- Vulns and advisories
- Incidents + exploit narratives
- Vendor and community disclosures
Flagship sampleUnlocked today
A global operation led by Europol and Microsoft has successfully dismantled the Tycoon 2FA phishing-as-a-service platform, which was responsible for a signif...
ENERGY
Daily briefings on the energy transition: policy, grid, storage, and markets.
Best for
- Grid + reliability narratives
- Policy + first-party data
- Storage + transition supply chain
Flagship sampleUnlocked today
Coverage discusses speculative scenarios around ~$20K; treat as market chatter and see linked sources.
BIOTECH
Daily briefings on clinical, regulatory, and R&D updates from public sources.
Best for
- Clinical + regulatory narratives
- Research + preprints
- Funding + market updates
Flagship sampleUnlocked today
J&J's Tecvayli claims third national priority FDA approval Phil.Taylor Fri, 06/03/2026 - 10:59.